![Filip Janku](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Filip Janku
Directeur Technique/Scientifique/R&D chez
MONTE ROSA THERAPEUTICS, INC.
Fortune : 1 M $ au 31/07/2026
Profil
Filip Janku is currently Chief Medical Officer at Monte Rosa Therapeutics, Inc. since 2021.
Formerly, served as Center Medical Director & Associate Professor at The University of Texas M.D.
Anderson Cancer Center from 2012 to 2021.
Education includes a doctorate from the University of Charles.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2026 | 60 612 ( 0,07 % ) | 1 M $ | 31/07/2026 |
Postes actifs de Filip Janku
| Sociétés | Poste | Début |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2021 |
Anciens postes connus de Filip Janku
| Sociétés | Poste | Fin |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | 01/05/2021 |
Formation de Filip Janku
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
37
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
University of Charles
 University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
